Navigation Links
Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
Date:4/18/2013

LONDON, April 18, 2013 /PRNewswire/ -- Replikins Ltd will reveal details on the availability of two completely synthetic vaccine candidates, both with long-term prevention goals and acute short-term blocking capacity.  One of these vaccines targets H7N9 alone, the other for H7N9 plus the other common influenza strains. The company is exploring partnerships with established healthcare and pharmaceutical companies to aggressively commercialize the technology. 

Because Replikins is leveraging proprietary software techniques to isolate targeted regions in the virus, combined with recent advances in manufacturing synthetic peptides, the company and its partners are able to provide rapid turnaround of vaccine candidates based on early data emerging from disease outbreaks.  This approach stands in marked contrast to projections by other companies of delays of seven months or longer before vaccines can be made available, and makes it possible to consider effective public health responses to disease outbreaks while they are still at an early stage.

Replikins will provide details of the technology and is seeking partnerships at the BIO International Convention April 22nd-25th at its booth #3456, McCormick Place, Chicago.

The technique used to create Replikins' new synthetic vaccine candidates is similar to those the company used in manufacturing a successful Replikins H5N1 "bird flu" vaccine in chickens in a paper published in 2009.  That vaccine was produced in 7 days, shipped freeze-dried, and administered via the respiratory tract.  Significantly, in addition to stopping the virus in the chickens, excretion of the virus was completely prevented, thus potentially interfering with the build-up of virus reservoirs which encourage mutations.

Contact: Dr. Samuel Bogoch , 646-320-5910, Email

References:

1.  Nature Precedings.  Bogoch et al, doi:10.1038/npre.2012.6952.1

(see also seven additional  Nature Precedings Publications, Bogoch 2011-2012. http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f60642.

2.  www.replikins.com

3. Dr. Sanjay Gupta of CNN Reports on Replikins (www.replikins.com)

4. Jackwood et al. Avian Diseases 53(4): 613‐617, 2009

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Replikins
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
2. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Generex Announces Details of Investor Conference Call
5. White Paper Details Five Things to Consider Before Buying Spiral Bevel Gear Drives
6. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
7. New Report Details NCPA Efforts to Drive Greater Medication Adherence
8. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
9. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
10. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
11. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... June 23, 2016  Guerbet announced today that it ... Supplier Horizon Award . One of 12 ... recognized for its support of Premier members through exceptional ... excellence, and commitment to lower costs. ... recognition of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):